mail ?,
"rock, lots of talk on other boards in regards to a JV in South Korea with CHA and possibly filing an IND? Your thoughts on this?"
To be blunt, it makes no sense. Given the following, why would CHA need to JV with ACT when CHA has the exclusive to develop and commercialize in South Korea? CHA has paid $1.7MM for these licenses and has the muscle to pursue themselves. So what would be the reason for a JV with ACT when they have license to it all? It certainly isn't for ACT's clinical trial experience..:)
CHA could file an IND for RPE anytime but maybe they would like to see things move forward here prior to spending the coin for trials there?. They have everything they need to pursue on their own, imo..
Exclusive License Agreement for ACTC's Single Cell Biopsy Technique..
Cha paid ACT $300K
Exclusive License Agreement for ACTC's RPE Technology, SCNT technology and other technical info...
CHA paid ACT $1.4 Million to date. Another $500K due ACT if CHA receives Korean grant for no less than $7.5 Billion WON.
